Original Article

Thioredoxin-1 and oxidative stress status in pregnant women at early third trimester of pregnancy: relation to maternal and neonatal characteristics

Yoko Nakatsukasa, Hirokazu Tsukahara, Kazuhide Tabuchi, Masako Tabuchi, Tomoko Magami, Mutsuko Yamada, Yosuke Fuji, Masato Yashiro, Mitsuru Tsuge, and Tsuneo Morishima

1Departments of Pediatrics and 2Gynecology and Obstetrics, Perineito Hahatokono Hospital for Mothers and Children, Okayama 703-8263, Japan
2Department of Pediatrics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan

(Received 15 July, 2012; Accepted 6 August, 2012; Published online 24 October, 2012)

This study examined the clinical and biological importance of thioredoxin-1, a redox-active defensive protein that controls multiple biological functions, in pregnant women. We measured serum concentrations of thioredoxin-1, total hydroperoxides, and redox potential in 60 pregnant women at the early third trimester: gestational age of 27–29 weeks. The thioredoxin-1 concentration (mean ± SD) was 90 ± 42 ng/ml. Total hydroperoxides was 471 ± 105 U.CARR (1 U.CARR = 0.08 mg/dl H₂O₂). Redox potential was 2142 ± 273 µmol/l. The total hydroperoxides: redox potential ratio (oxidative stress index) was 0.23 ± 0.08. Thioredoxin-1, total hydroperoxides, and oxidative stress index were higher and redox potential was lower than in blood of healthy adults. Total hydroperoxides and redox potential were mutually correlated significantly and negatively. Thioredoxin-1 correlated significantly and negatively and redox potential correlated significantly and positively with body weight and body mass index. Thioredoxin-1 and oxidative stress status were significantly and positively correlated with thioredoxin-1 and oxidative stress status significantly and positively with body weight and body mass index. Thioredoxin-1 and redox potential correlated significantly and positively with uric acid and albumin, respectively. Thioredoxin-1 and oxidative stress index correlated significantly and negatively and redox potential significantly and positively with neonatal birth weight. These results suggest that high concentrations of thioredoxin-1 are linked to high oxidative stress status in pregnant women and that neonatal birth weight is affected by the maternal oxidative condition during later pregnancy.

Key Words: later pregnancy, oxidative stress, redox potential, thioredoxin, total hydroperoxides

Aerobic organisms normally generate reactive oxygen-derived species (ROS) during respiration and metabolism processes. However, when the generation of ROS exceeds the antioxidant defense capacity, ROS can damage cellular macromolecules including proteins, lipids, and nucleic acids. Increased generation of ROS during growth of the fetal-placental unit is a prominent feature of pregnancy. Further enhancement of oxidative stress is likely to promote several pregnancy-related disorders including preeclampsia, fetal growth restriction (FGR), preterm labor, and low birth weight.

Thioredoxin (TRX) is a ubiquitously expressed, multifunctional protein (12-kDa) that has a redox-active dithiol-disulfide within the conserved Cys-Gly-Pro-Cys sequence. This defensive protein is induced in response to various stress conditions. Thioredoxin plays a crucial role in ROS detoxification and transcription factor regulation, each of which is critical to normal cellular function. Human-TRX-overexpressing transgenic mice survive longer and are more resistant to various oxidative conditions than control mice are.

Thioredoxin is expressed in human decidua and trophoblasts, where it might protect the fertilized egg and placental trophoblasts from the cytotoxic effects of ROS. Histological examination of the human placenta has revealed that TRX is expressed in cytotrophoblasts, decidual cells, and stromal cells in the stem villi. Moreover, examination of human fetal tissues has revealed that TRX is distributed widely in different tissues and organs. Overexpression of TRX-1 reduces oxidative stress in the placenta of transgenic mice and TRX-1 might promote normal growth and development in the mouse fetus. These findings suggest that TRX plays a role in growth and development of the fetal-placental unit in humans. For this study, we measured serum concentrations of TRX-1 in pregnant women at the early third trimester of pregnancy. We determined total hydroperoxides (TH) and redox potential (RP) in the sera for comparison. We also examined whether the concentrations of those parameters were associated with subsequent pregnancy and birth outcomes. This report describes high serum concentrations of TRX-1 and TH in pregnant women and presents findings related to maternal and neonatal characteristics.

Materials and Methods

Participants. During August 2011–November 2011, pregnant women at the early third trimester were asked to participate in this study. They had visited Perineito Hahatokono Hospital for Mothers and Children, which is located in Okayama, Japan. Exclusion criteria were the following: non-Japanese, date of last menstrual period uncertain, age <20 years or ≥40 years, multiple pregnancy, smoking or drinking habits, intake of multivitamins, hypertensive (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) or infectious condition, history of chronic condition (such as cardiovascular, renal, metabolic, immunological, and neurological diseases).

In this study, 60 pregnant women were enrolled. Each gave written informed consent before entering the study. The study, which was approved by the local ethics committee, was performed according to the Declaration of Helsinki.

To whom correspondence should be addressed. E-mail: hirokazu010661@yahoo.co.jp
Clinical and laboratory data. Gestational age (GA) was estimated based on reported data of the subject’s last menstruation and ultrasound measurements performed by obstetricians. Body weight and height, by which the body mass index (BMI) was calculated, and blood pressure were recorded by trained nurses. Non-hemolytic venous blood was sampled for measurement of AST, ALT, LD, creatinine, uric acid, albumin, and glucose using automated analyzers with commercially available kits. Thioredoxin-1 and other oxidative stress biomarkers were measured in the sera using the methods described below.

Assay of TRX-1. Thioredoxin-1 was measured using a sensitive sandwich ELISA system (Redox Bioscience Inc., Kyoto, Japan) according to the procedure described previously. Two specific mouse monoclonal antibodies to non-overlapping epitopes of human TRX-1 (ADF 11 and ADF 21) were used. These antibodies do not cross-react to mitochondrial TRX, TRX-2.

Epitopes of human TRX-1 (ADF 11 and ADF 21) were used. Two specific mouse monoclonal antibodies to non-overlapping epitopes of human TRX-1 (ADF 11 and ADF 21) were used. These antibodies do not cross-react to mitochondrial TRX, TRX-2.

Neonatal characteristics at birth. The recorded neonatal characteristics were the following: mode of delivery, sex, GA, birth weight (BW) and BW SD score at each GA, Apgar scores, pH and HCO₃⁻ value in umbilical cord blood.

Statistical analysis. Data are presented as mean ± SD and/or range (minimum–maximum). Differences between groups were examined using unpaired t test. Correlations between variables were assessed using Pearson correlation coefficients. Differences for which p<0.05 were regarded as significant. All statistical calculations were performed using GraphPad Prism 5.0 (GraphPad Software Inc., San Diego, CA).

Results

Characteristics of the 60 subjects. The age of the subjects was 31 ± 5 years (21–39 years). Of the 60 women, 25 women (42%) were primigravid and 35 (58%) were multigravid. Venous blood was sampled at the GA of 28±1 weeks (27–29 weeks). They showed no abnormal results for serum AST, ALT, LD, creatinine, uric acid, albumin, or glucose. Clinical and laboratory data of the subjects are presented in Table 1.

### Table 1. Characteristics of 60 pregnant women at the early third trimester

| Age (years) | 31 ± 5 (21–39) |
|-------------|---------------|
| Gestational age (weeks) | 28 ± 1 (27–29) |
| Weight (kg) | 59 ± 9 (46–95) |
| Height (m) | 159 ± 6 (145–173) |
| Body mass index (kg/m²) | 23 ± 3 (18–35) |
| Systolic blood pressure (mm Hg) | 96 ± 9 (72–123) |
| Diastolic blood pressure (mm Hg) | 54 ± 8 (23–71) |
| AST (IU/l) | 15 ± 3 (10–28) |
| ALT (IU/l) | 10 ± 5 (4–27) |
| LD (IU/l) | 167 ± 18 (132–217) |
| Creatinine (mg/dl) | 0.45 ± 0.06 (0.35–0.58) |
| Uric acid (mg/dl) | 3.1 ± 0.6 (1.8–4.9) |
| Albumin (g/dl) | 3.4 ± 0.2 (3.0–3.9) |
| Glucose (mg/dl) | 77 ± 11 (64–137) |

Data are expressed as mean ± SD and range.

Serum concentrations of TRX-1, TH, RP, and OSI. Table 2 shows the serum concentrations of thioredoxin-1, TRX-1, TH, RP, and OSI in the pregnant women at the early third trimester. The TRX-1 was 42 ± 2 (11–205) ng/ml. TH was 471 ± 105 (193–708) U.CARR. RP was 2142 ± 273 (1430–2601) µmol/l. OSI was 0.23 ± 0.08 (0.09–0.45).

### Table 2. Serum concentrations of thioredoxin-1 and other oxidative stress biomarkers in 60 pregnant women

| Thioredoxin-1 (ng/ml) | 90 ± 42 (11–205) |
| Total hydroperoxides (U.CARR) | 471 ± 105 (193–708)* |
| Redox potential (µmol/l) | 2142 ± 273 (1430–2601)* |
| Oxidative stress index | 0.23 ± 0.08 (0.09–0.45) |

Data are expressed as mean ± SD and range. "Oxidative stress index" is defined as the ratio of total hydroperoxides (U.CARR) to redox potential (µmol/l). *A significant and negative correlation was found between total hydroperoxides and redox potential. (r = -0.46, p = 0.0002).

Correlations between oxidative stress biomarkers and clinical and laboratory data. Correlations between oxidative stress biomarkers (TRX-1, TH, RP, OSI) and clinical data (age, body weight, height, BMI, blood pressures) were assessed. Statistical significance was found only for TRX-1 vs BW (r = -0.27, p = 0.036), TRX-1 vs BMI (r = -0.26, p = 0.041), RP vs BW (r = -0.33, p = 0.010), and RP vs BMI (r = 0.36, p = 0.005).

The respective correlations between oxidative stress biomarkers and biochemistry values (AST, ALT, LD, creatinine, uric acid, albumin, glucose) were also assessed. Statistical significance was found only for TRX-1 vs uric acid (r = -0.34, p = 0.008) and RP vs albumin (r = 0.29, p = 0.022).
Relation with pregnancy outcome. Of the 60 women, three subsequently developed nonsevere hypertension. No significant difference was identifiable in those levels between the women who developed hypertension (n = 3) and those who did not (n = 57). The TRX-1 was 79 ± 44 ng/ml and 90 ± 42 ng/ml, TH was 425 ± 97 U.CARR and 473 ± 105 U.CARR, RP was 2161 ± 251 µmol/l and 2141 ± 276 µmol/l, and OSI was 0.20 ± 0.05 and 0.23 ± 0.08, respectively. None of the 60 women developed diabetes mellitus or other critical disorder during later pregnancy.

Relation with birth outcome. None of the 60 women gave birth to infants with congenital anomalies or those requiring intensive clinical care such as neonatal asphyxia, respiratory distress syndrome, sepsis, or organ failure. The neonatal characteristics are presented in Table 3. Of the neonates, 56 were born at term and 4 were born preterm. No neonate had been asphyxiated at birth. Their Apgar scores and pH and HCO₃⁻ values in umbilical cord blood were not abnormally low. When correlations between oxidative stress biomarkers and the BW or BW SD score of the neonates were tested, statistical significance was found for TH vs BW (r = –0.26, p = 0.046), RP vs BW (r = 0.31, p = 0.018), and OSI vs BW (r = –0.33, p = 0.010). Fetal growth restriction criteria are BW less than the tenth percentile of standard values at each GA.(26) No significant difference was found in those levels between the FGR group (n = 5) and the non-FGR group (n = 55). The TRX-1 was 103 ± 37 ng/ml and 88 ± 43 ng/ml, TH was 477 ± 121 U.CARR and 470 ± 104 U.CARR, RP was 2125 ± 219 µmol/l and 2142 ± 279 µmol/l, and OSI was 0.23 ± 0.07 and 0.23 ± 0.08.

Discussion

Pregnancy per se is a state of oxidative stress arising from increased placental metabolic activity and increased production of ROS and relatively reduced total antioxidant capacity.(2) Concentrations of oxidative stress biomarkers, including blood lipid peroxides, oxidized LDL, and 8-isoprostane and urinary 8-hydroxydeoxyguanosine,(1) became higher toward the third trimester of pregnancy than in non-pregnant women.(3,4,10) Notably, serum TH values (using the d-ROM kit) in pregnant women at 27–31 weeks of gestation were elevated (531 ± 143 U.CARR; range 153–895 U.CARR).(11) Those values showed significant and positive correlations with body weight and both systolic and
Regarding antioxidants, erythrocyte activities of glutathione peroxidase and superoxide dismutase increased toward the third trimester of pregnancy. In contrast, the RP values determined by the ferric reducing ability of plasma test, which exploits the same chemical principle of the BAP kit, were lower in pregnant women than in non-pregnant women.

In addition, the serum RP values determined using 2,2′-azino-di-(3-ethylbenzthiazoline sulfonate) were reported to decrease gradually as pregnancy advances. Collectively, these results indicate that the total antioxidant capacity in plasma or serum is not enhanced in spite of the presence of oxidative stress during later pregnancy.

Only one study has measured serum TRX-1 concentrations in pregnant women. Kuroda and coworkers reported that serum TRX-1 concentrations are elevated during pregnancy. The TRX-1 concentrations were, respectively, 57 ± 26 ng/ml, 66 ± 25 ng/ml, and 66 ± 23 ng/ml in the first, second, and third trimesters of pregnancy, as compared to the non-pregnant control values (48 ± 26 ng/ml). The physiological increase of TRX-1 concentrations supports the contention that TRX-1 is involved in the maintenance of normal pregnancy in humans. Our earlier report described that the TRX-1 concentrations in umbilical cord blood (127 ± 81 ng/ml) and those in early breast milk (268 ± 149 ng/ml) are elevated remarkably. These results indicate that the systemic release of TRX-1 is enhanced in neonates at birth and that early breast milk is a rich source of this protein.

In this study, we measured serum TRX-1 concentrations in 60 pregnant women at the early third trimester. Results showed that their TRX-1 concentrations (90 ± 42 ng/ml) were several times higher than healthy adult values (10–30 ng/ml). The results are consistent with data presented by Kuroda and coworkers. We measured the oxidative stress status further in pregnant women using d-ROM and BAP tests. The TH values were higher, but the RP values were lower in the pregnant women, as compared to healthy adult values.

Accordingly, the OSI (0.23 ± 0.08) was about two times higher than the healthy adult level (around 0.1). The RP values were found to have significant and negative correlation with the TH values in the subjects, thereby implying that antioxidant buffering capacity is attenuated as the oxidative load increases. The results suggest that the high concentrations of TRX-1 are linked to physiologically high oxidative stress status and reduced antioxidant capacity in pregnant women, although the TRX-1 concentrations per se were not correlated directly with the other oxidative stress markers.

Among the correlations analyzed statistically, TRX-1 and RP respectively showed significant negative and positive correlations with each of BW and BMI in these pregnant women. Although the causal relation remains unclear, these results suggest that systemic release of TRX-1 and total antioxidant capacity in serum are related closely to maternal body size. Additionally, it is intriguing that TRX-1 and RP showed significant and positive correlations with uric acid and albumin, respectively, in the subjects. Uric acid is recognized as a marker of oxidative stress. Uric acid functions not only as an antioxidant but also as a pro-oxidant. The physiological role of uric acid in the fetal-placental unit might be complex and multifactorial. The BAP kit does not measure individual antioxidants. It measures the overall effect of many non-enzymatic antioxidants. Albumin, which is present in high concentrations in blood, scavenges various strong oxidants. Our results support the contention that albumin contributes substantially to the RP value determined by the BAP kit.

Enhancement of oxidative stress during pregnancy has emerged as a likely promoter of preeclampsia, diabetes mellitus, FGR, and other pregnancy-related disorders. Previous histological examinations revealed that the levels of 4-hydroxynonenal, TRX, glutaredoxin, and protein disulfide isomerase were increased in the placenta in preeclampsia than in uncomplicated pregnancy and that levels of 8-hydroxydeoxyguanosine and TRX were higher in the placenta in cases of preeclampsia or FGR than in uncomplicated pregnancy during the third trimester. These results indicate that TRX might be induced adaptively against oxidative stress in the placenta in preeclampsia or FGR.

In this study, no significant difference was found in the biomarkers of women who developed hypertension and those who did not, or between those who developed FGR and those who did not. We must admit that the subjects with critical complications were very few. The predictive value of serum TRX-1 (together with TH, RP, OSI) for the development of pregnancy-related disorders should be evaluated thoroughly in future studies.

Thioredoxin is known to be expressed widely in the human female reproductive system, including placenta, fetus, ovary, endometrium, and cervix. The increase in TRX expression occurs preferentially in the functionally active tissues and cells in this system. Reportedly, TRX plays a role in reproduction as a component of the “early pregnancy factor.” Target disruption of the mouse TRX-1 gene results in early embryonic lethality. Moreover, TRX-1 is likely to be synthesized in high amounts in breast tissues of lactating women. These findings, together with our present results, indicate that TRX-1 provides a unique protective mechanism that allows the maintenance of redox balance in the female reproductive processes and outcomes.

This study has some limitations that must be addressed in future research. First, our study involves a small population, with no direct measurement of fetal or neonatal oxidative stress status. Second, information about dietary habits of the subjects was not available. Third, the samples are not representative of pregnant women in general because the data were of a hospital-based study. Finally, the study design is limited by its cross-sectional nature. A longitudinal study is necessary to ascertain the predictive ability of the parameters for pregnancy and birth outcomes.

In conclusion, this study documents that serum concentrations of TRX-1, TH, and OSI are higher and RP is lower in pregnant women at the early third trimester than in healthy adults and that the TH and RP correlate significantly and negatively. This study also demonstrates that TRX-1 correlates significantly and negatively and RP correlates significantly and positively with body weight and body mass index in the pregnant women. Moreover, TRX-1 and OSI correlate significantly and negatively and RP correlates significantly and positively with neonatal birth weight. These results suggest that the high concentrations of TRX-1 are linked to high oxidative stress status in pregnant women and that neonatal birth weight is affected by the maternal oxidative condition during later pregnancy.

Acknowledgments

We thank all members of the Nursing Facility, Perineito Hahatokono Hospital for Mothers and Children for their kind assistance. This work was supported by a research grant from the Japanese Ministry of Health, Labour and Welfare.

Abbreviations

| Abbreviation | Definition               |
|--------------|-------------------------|
| BMI          | body mass index         |
| BW           | birth weight            |
| FGR          | fetal growth restriction|
| GA           | gestational age         |
| OSI          | oxidative stress index  |
| ROS          | reactive oxygen-derived species |
| RP           | redox potential         |
| TH           | total hydroperoxides    |
| TRX          | thioredoxin             |

Conflict of Interest

No potential conflicts of interest were disclosed.
References

1 Tsukahara H. Biomarkers for oxidative stress: clinical application in pediatric medicine. *Curr Med Chem* 2007; **14**: 339–351.

2 Myatt L, Cui X. Oxidative stress in the placenta. *Histochim Cell Biol* 2004; **122**: 369–382.

3 Toescu V, Nuttall SL, Martin U, Kendall MJ, Dunne F. Oxidative stress and normal pregnancy. *Clin Endocrinol (Oxf)* 2002; **57**: 609–613.

4 Belo L, Caslake M, Santos-Silva A, et al. LDL size, total antioxidant status and oxidised LDL in normal human pregnancy: a longitudinal study. *Atherosclerosis* 2004; **177**: 391–399.

5 Kodama H, Shinohara H, Nakazaka A, Narita Y, Yoshida M. Implications of an oxidative stress marker, serum hydroxyperoxide concentration, in the medical checkup of pregnant women at around 30 weeks of gestation. *Maternal Health* 2008; **49**: 98–106 (Japanese).

6 Hung TH, Lo LM, Chiu TH, et al. A longitudinal study of oxidative stress and antioxidant status in women with uncomplicated pregnancies throughout gestation. *Reprod Sci* 2010; **17**: 401–409.

7 Siddiqui IA, Jaleel A, Tamimi W, Al Kadri HM. Role of oxidative stress in the pathogenesis of preeclampsia. *Arch Gynecol Obstet* 2010; **282**: 469–474.

8 Al-Gubory KH, Fowler PA, Garrel C. The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes. *Int J Biochem Cell Biol* 2010; **42**: 1634–1650.

9 Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. *Annu Rev Immunol* 1997; **15**: 351–369.

10 Nakamura H, Hoshino Y, Okuyama H, Matsuo Y, Yodoi J. Thioredoxin 1 delivery as new therapeutics. *Adv Drug Deliv Rev* 2009; **61**: 303–309.

11 Mitsui A, Hamuro J, Nakamura H, et al. Overexpression of human thioredoxin in transgenic mice controls oxidative stress and life span. *Antioxid Redox Signal* 2002; **4**: 693–696.

12 Takagi Y, Mitsui A, Nishiyama A, et al. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. *Proc Natl Acad Sci USA* 1999; **96**: 4131–4136.

13 Shioji K, Kishimoto C, Nakamura H, et al. Overexpression of thioredoxin-1 in transgenic mice attenuates adriamycin-induced cardiotoxicity. *Circulation* 2002; **106**: 1403–1409.

14 Kusunoki K, Nakamura H, Ono T, Muso E, Yodoi J. Protective roles of thioredoxin, a redox-regulating protein, in renal ischemia/reperfusion injury. *Kidney Int* 2003; **64**: 1273–1282.

15 Kobayashi F, Sagawa N, Nanbu Y, et al. Biochemical and topological analysis of adult T-cell leukaemia-derived factor, homologous to thioredoxin, in the pregnant human uterus. *Hum Reprod* 1995; **10**: 1603–1608.

16 Di Trapani G, Perkins A, Clarke F. Production and secretion of thioredoxin from transformed human trophoblast cells. *Mol Hum Reprod* 1998; **4**: 369–375.

17 Ejima K, Namn H, Toki N, Kashimura M, Ikeda M. Localization of thioredoxin reductase and thioredoxin in normal human placenta and their protective effect against oxidative stress. *Placenta* 1999; **20**: 95–101.

18 Fujii S, Nanbu Y, Konishi I, Mori T, Masutani H, Yodoi J. Immunohistochemical localization of adult T-cell leukaemia-derived factor, a human thioredoxin homologue, in human fetal tissues. *Virchows Arch A Pathol Anat Histopathol* 1991; **419**: 317–326.

19 Matsui M, Oshima M, Oshima H, et al. Early embryonic lethality caused by targeted disruption of the mouse thioredoxin gene. *Dev Biol* 1996; **178**: 179–185.

20 Unoekawa T, Sugiyama T, Kihira T, et al. Overexpression of thioredoxin-1 reduces oxidative stress in the placenta of transgenic mice and promotes fetal growth via glucose metabolism. *Endocrinology* 2008; **149**: 3980–3988.

21 Kamimoto Y, Sugiyama T, Kihira T, et al. Transgenic mice overproducing human thioredoxin-1, an antioxidant and anti-apoptotic protein, prevents diabetic embryopathy. *Diabetologia* 2010; **53**: 2046–2055.

22 Ezaki S, Suzuki K, Kurushima C, et al. Resuscitation of preterm infants with reduced oxygen results in less oxidative stress than resuscitation with 100% oxygen. *J Clin Biochem Nutr* 2009; **44**: 111–118.

23 Todoroki Y, Tsukahara H, Ohshima Y, et al. Concentrations of thioredoxin, a redox-regulating protein, in umbilical cord blood and breast milk. *Free Radic Res* 2005; **39**: 291–297.

24 Nojima J, Miyakawa M, Kodama M, et al. Measurement of the oxidation stress degree by the automated analyzer JCA-BM 1650. *Jpn J Med Technol* 2010; **59**: 199–207 (Japanese).

25 Hussein MH, Hashimoto T, Daoud GA, et al. Oxidative stress after living related liver transplantation subsides with time in pediatric patients. *Pediatr Surg Int* 2011; **27**: 17–22.

26 Itabashi K, Fujimura M, Kusuda S, et al. New birth size standards by gestational age for Japanese neonates. *J Jpn Soc Pediatr* 2010; **114**: 1271–1293 (Japanese).

27 Kuroda S, Watanabe M, Santo T, et al. Postpartum increase of thioredoxin concentrations and the relation to CD8 lymphocytes. *Ann Clin Biochem* 2010; **47**: 62–66.

28 Pasalic D, Marinkovic N, Feher-Turkovic L. Uric acid as one of the important factors in multifactorial disorders—facts and controversies. *Biochem Med (Zagreb)* 2012; **22**: 63–75.

29 Kaneko K, Kimata T, Tsuji S, Shimo T, Takahashi M, Tanaka S. Serum albumin level accurately reflects antioxidant potentials in idiopathic nephritic syndrome. *Clin Exp Nephrol* 2012; **16**: 411–414.

30 Rogers MS, Wang CC, Tam WH, Li CY, Chu KO, Chu CY. Oxidative stress in midpregnancy as a predictor of gestational hypertension and pre-eclampsia. *BJOG* 2006; **113**: 1053–1059.

31 Potdar N, Singh R, Mistry V, et al. First-trimester increase in oxidative stress and risk of small-for-gestational-age fetus. *BJOG* 2009; **116**: 637–642.

32 Min J, Park B, Kim YJ, Lee H, Ha E, Park H. Effect of oxidative stress on birth sizes: consideration of window from mid pregnancy to delivery. *Placenta* 2009; **30**: 418–423.

33 Shibata E, Ejima K, Nanri H, et al. Enhanced protein levels of protein thiol/disulfide oxidoreductases in placentae from pre-eclamptic subjects. *Placenta* 2001; **22**: 566–572.

34 Takagi Y, Nakaido T, Toki T, et al. Levels of oxidative stress and redox-related molecules in the placenta in preeclampsia and fetal growth restriction. *Vircchows Arch* 2004; **444**: 49–55.

35 Iwai T, Fujii S, Nanbu Y, et al. Expression of adult T-cell leukaemia-derived factor, a human thioredoxin homologue, in the human ovary throughout the menstrual cycle. *Vircchows Arch A Pathol Anat Histopathol* 1992; **420**: 213–217.

36 Maruyama T, Kitaoka Y, Sachy Y, et al. Thioredoxin expression in the human endometrium during the menstrual cycle. *Mol Hum Reprod* 1997; **3**: 989–993.

37 Sahlin I, Stjernholm Y, Holmgren A, Ekmak G, Eriksson H. The expression of thioredoxin mRNA is increased in the human cervix during pregnancy. *Mol Hum Reprod* 1997; **3**: 1113–1117.

38 Clarke FM, Orozco C, Perkins AV, et al. Identification of molecules involved in the ‘early pregnancy factor’ phenomenon. *J Reprod Fertil* 1991; **93**: 525–533.